Delivery Order SPE2DR25D1017-SPE2DR26F9DVC
- Not listed
- This delivery order, awarded on January 7, 2026, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of Diclofenac-Misoprostol 50-0.2 mg tablets in quantities of 60 units, with a ceiling value of $2,760.75. The contract represents a firm fixed-price delivery order with an ultimate completion date of January 8, 2026, and was competitively awarded without set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of 1,000 tablets of Diclofenac Sodium 75 mg, a nonsteroidal anti-inflammatory medication commonly used for pain management. The contract carries a ceiling value of $1,193.41 and represents a firm fixed-price delivery order with an ultimate completion date of November 5, 2025. This award was competitively awarded with no set-aside designation and will be performed at the...
- The Defense Logistics Agency (DLA) awarded a $8,442.29 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Diclofenac Potassium 50 mg on December 30, 2025, with a completion date of December 31, 2025. This non-set-aside contract employs firm fixed price terms and is classified as a child award under AmerisourceBergen's larger indefinite delivery contract with the DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,613.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Diclofenac Sodium 1% Gel in 100-gram units, with an ultimate completion date of September 22, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 31, 2025, for the supply of Diclofenac Potassium 50 mg powder packets (9 count) with a ceiling value of $1,754.62. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of 4,565,784,264 units of Diclofenac Potassium 50 mg tablets in 100-count bottles. The contract has a firm-fixed price of $1,931.08 and a completion date of September 13, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Diclofenac Sodium 1% Gel (100GM) with a ceiling value of $1,466.40. This non-competitive, firm fixed-price delivery order was executed on September 25, 2025, with an ultimate completion date of September 26, 2025. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,395.27, is for the delivery of 100 mg tablets of the drug diclofenac sodium extended-release. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of December 19, 2023. The contract is not designated with a set-aside....
- This federal contract award, valued at $1,493.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order for the supply of 4,568,201,898 units of Diclofenac Sodium Delayed-Release 75 mg tablets. The contract has a firm fixed price and an ultimate completion date of May 12, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,953.10 to AmerisourceBergen Drug Corp for Diclofenac Sodium 1% Gel in 100-gram units on December 4, 2025, with an ultimate completion date of December 5, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded under DLA's procurement process. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F9DVCDelivery Order
The Defense Logistics Agency awarded a $1,157.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Diclofenac-Misoprostol 75-0.2 mg tablets (60-count units) with a completion date of January 26, 2026. This is a non-set-aside, competitively awarded contract to be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen, a subsidiary of parent company Cencora, Inc., serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The prime IDC vehicle enables the contractor to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The diclofenac-misoprostol combination product represents a routine pharmaceutical procurement supporting Defense Health Agency and other federal healthcare system requirements for pain management and gastrointestinal protection.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 1/22/26 |